Significant innovations and the close cooperation between research and development form the basis for the success of more than 250 biotechnology companies located here. Top-class research institutions, leading SMEs, and strong multinational corporations form a network that ensures healthy growth and that attracts researchers and capital from around the entire world. This is evident in the constantly increasing number of biotechnology patents in Switzerland.
As an important European Life Sciences stock exchange, Switzerland offers an outstanding framework for procuring capital. The SIX Swiss Exchange invests 40% of its traded capital in Life Sciences projects. The economic and scientific environment boasts the presence of successful international chemical and pharmaceutical companies, such as Novartis and Roche, as well as innovative firms from the medical technology, biotechnology, and nanotechnology sectors, making it highly suitable for strategic partnerships, licensing, or patent sales. Modern infrastructure, high quality of life, and access to excellently trained employees supplement the extremely positive conditions for a strong and future-oriented biotechnology industry in Switzerland.